About Us

About Us Image

Living life without fear, in the calm and confidence we all deserve.

VydaMed, Inc. is set to revolutionize anxiety management with its cutting-edge wearable device technology and mobile application, paving the way for enhanced mental wellness and redefining industry standards.

Founded by industry veteran, Eyad Kishawi, and inspired by Noah Hohner, VydaMed will introduce a non-invasive neuromodulation wearable and companion app that will combine three unique concepts:

  • Non-Invasive Stimulation of the Vagus Nerve
  • Closed-Loop Dynamic Regulation of the Nervous System
  • Evidence-Based Anxiety Reduction and Therapy Techniques

This fusion of innovation empowers individuals to conquer anxiety and achieve lasting mental well-being. This is achieved through VydaMed’s ability to dynamically stimulate the auricular branch of the Vagus Nerve, triggering the parasympathetic nervous system for quick self-calming capabilities. With the wearable able to meticulously track physiologic parameters and seamlessly sync with the app, users gain invaluable behavioral guidance. By harnessing the power of neuroplasticity, VydaMed is able to empower its patients to effectively manage anxiety over the long term – backed by closed-loop regulation and measurable metrics for anxiety levels.

Driven by a dedicated team of professionals, including industry trailblazer Eyad Kishawi and visionary founder Noah Hohner, who experienced first-hand the profound impact of anxiety disorder, VydaMed is also guided by internationally renowned Doctors and Clinicians hailing from University of California, San Francisco.

Guided by their expertise, alongside VydaMed’s user-centric approach and groundbreaking technology, VydaMed is confident it will forge a path towards a brighter, anxiety-free future for millions worldwide.

Founding Team


Eyad Kishawi

Co-founder and Chief Technology Officer (CTO)

Eyad Kishawi is a highly accomplished Medical Device Executive with an exemplary 30-year track record, marked by a series of exceptional achievements and transformative leadership.

Throughout his career, Eyad's extensive experience spans from working with small startups to large publicly traded companies, effectively guiding six different medical devices from conception to clinical adoption and commercialization. Notably, he played a pivotal role as the second technical hire in a successful neuromodulation startup that achieved an impressive exit valuation of $850 million, underscoring his visionary leadership and ability to drive innovation in the Medical Device industry.

Noah Hohner is a visionary entrepreneur who is driven by a profound passion to address the escalating prevalence of anxiety among youth. His personal journey battling Severe Anxiety Disorder during his formative years laid the foundation for a powerful mission - to create a positive impact and help others facing similar challenges.

As the brainchild behind the business concept, Noah's deep-rooted empathy and understanding of the complexities of anxiety have been instrumental in shaping VydaMed's transformative vision. While he may not be directly involved in the day-to-day operations anymore, his indelible imprint resonates through the company's core values and mission


Advisory Boards:


Gregory Cash

Business Advisory Board:

Gregory Cash is a seasoned Chief Executive Officer with over 45 years’ worth of experience within Life Sciences and Medical Devices, now lending his dynamic leadership to VydaMed as a Business Advisor. With his impressive track record, he has spearheaded publicly traded companies and orchestrated the successful scaling up of numerous medical device ventures. His invaluable insights are poised to propel VydaMed's growth and success in the competitive healthcare landscape, making Mr. Cash an indispensable driving force behind the Company's transformative achievements.

Scientific Advisory Board:

Professor Jess Ghannam, PhD, MSC, is a distinguished global leader within PTSD and complex anxiety research, currently the a Psychiatry professor at the University of California, San Francisco. He embodies an unwavering commitment spanning over 30 years, emerging as a prominent figure in advancing the science and treatment of anxiety disorders. As an accomplished clinician, researcher, and educator, Professor Ghannam's contributions have left an indelible mark on the field.

Beyond academia, he has played an instrumental role in consulting and supporting the inception and market introduction of several biopsychtech devices that are now making a transformative impact in the treatment of psychiatric disorders worldwide. Professor Ghannam's guidance and expertise as a Scientific Advisor continue to propel VydaMed's mission to provide innovative solutions and lasting well-being for those grappling with anxiety challenges.


Investor Relations.